Currently, Mirum Pharmaceuticals Inc [MIRM] is trading at $45.03, up 2.20%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MIRM shares have gain 0.87% over the last week, with a monthly amount drifted -10.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on April 17, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $48. Previously, H.C. Wainwright reaffirmed its Buy rating on December 18, 2023, and dropped its price target to $58. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $60 on November 13, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $50 as its price target on October 24, 2023. In a note dated September 20, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
This stock has fluctuated between a low of $23.14 and a high of $54.23 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $45.03 at the most recent close of the market. An investor can expect a potential return of 55.45% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Trailing Twelve Months sales for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] were 336.89M which represents 42.93% growth. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.38 and Total Capital is -0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.16 points at the first support level, and at 43.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.96, and for the 2nd resistance point, it is at 46.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] is 3.10. Further, the Quick Ratio stands at 2.93, while the Cash Ratio is 1.76. Considering the valuation of this stock, the price to sales ratio is 6.55, the price to book ratio is 9.65.
Transactions by insiders
Recent insider trading involved Heron Patrick J, Director, that happened on Mar 10 ’25 when 1335.0 shares were purchased. Director, Heron Patrick J completed a deal on Mar 11 ’25 to buy 963.0 shares. Meanwhile, Director Heron Patrick J bought 1335.0 shares on Mar 06 ’25.
